After being fired, I became the light of medicine

Chapter 19 The last straw that broke the camel's back!
“No subsidies?”

Ren Xiaomin was stunned and a little confused.

But he reacted the next second.

"Zhang Yang, you don't want us to continue working on our own and move forward with the next phase III clinical trial, do you?"

Zhang Yang nodded heavily, and then recounted the incident that occurred in the hematology clinic a few days ago between Li Bing and others.

"In fact, I have noticed in the past few days that compared to when we first started recruiting patients, the difficulty of recruiting patients has been greatly reduced in the past half month!"

"Especially the last group of test subjects, almost all of them came here on their own initiative!"

"They don't care about the enrollment subsidy, they just want to try our 'Qingshan Avatrombopag'!"

"so!"

As he spoke, Zhang Yang's expression became serious:
"Since Ding Jian is deliberately doing bad things behind our backs, if stopping the patient subsidies can keep us going, then why don't we try to continue working on our own and complete the Phase III clinical trial ourselves?"

A hint of excitement also flashed in Ren Xiaomin's eyes.

Over the past few months, he has also been working tirelessly on the Phase II clinical trial of Qingshan Avatrombopag Tablets. Like Zhang Yang, he has long regarded this as his own career!
If it weren't for the pressure of reality, who would be willing to sell their business?
"Okay, I'll do it right away!"

Ren Xiaomin took out a piece of draft paper and started calculating quickly.

The clinical trial costs of an innovative drug are roughly divided into three parts.

The first part is the R&D expenses incurred during the continuous adjustment, improvement and revision of new drugs during the Phase II and Phase III clinical trials.

No innovative drug is achieved overnight. During the clinical cycle of several years, pharmaceutical companies will repeatedly improve key factors such as innovative ingredients and dosage by obtaining clinical data and side effects.

The more adjustments you make, the higher the cost; the larger the modification, the greater the cost will naturally be.

This part is also the most expensive item in clinical trial costs.

of course.

For the complete product "Qingshan Avaqubopa Tablets", there is no such expense at all.

The second part is the patient’s subsidy.

The subsidy for each new drug could be as low as a few hundred yuan or as high as ten thousand, twenty thousand, or thirty thousand yuan.

In addition to cash subsidies, major pharmaceutical companies will also provide a variety of benefits such as "subsidized hospitalization expenses", "reduced treatment cost subsidies", "free medication" and so on according to actual conditions.

In short, the purpose is to attract more qualified subjects to join the group.

A good subsidy plan was also provided during the Phase II trial of Qingshan Avatrombopag Tablets.

Each subject who successfully joins the group will not only receive a cash subsidy of 7000 yuan, but also an additional travel subsidy of 500 yuan for each follow-up examination at the hospital.
After calculation, each patient received a subsidy of 1.3 yuan, and the 105 subjects received a total subsidy of 140 million yuan.

This is just the cost for the second phase with only 105 people. The third phase of clinical trials will not only have more people but also a longer period. A rough estimate of the cost is tens of millions!

The third part is the patient's examination fees and the hospital's cooperation fees.

The examinations required for a new drug clinical trial are not as simple as those experienced by ordinary people in the hospital. Not only are there many examination items involved, but some of them are also very expensive.
Moreover, the number of inspections is far beyond what most people imagine.

Take the Phase III clinical trial plan designed for Qingshan Avatrombopag as an example. There are a total of 16 checkpoints during the three-month clinical trial period, including 12 general inspections and 4 comprehensive inspections.

These costs are all borne by pharmaceutical companies!
In addition to this are the hospital's cooperation fees and routine fees. After all, without the strong support of various departments of the hospital, it is almost difficult to promote the clinical trials of new drugs.

And now, Zhang Yang has to bear this part of the cost!

After a while, Ren Xiaomin calculated the result!

"Zhang Yang, if we calculate based on the 600 patients in the Phase III clinical trial we applied for, the cost of the examination plus some miscellaneous expenses can be controlled between 800 million and 1000 million." "Of course, this is the most ideal situation, and there can be no accidents."

"Ah."

Zhang Yang nodded, the data was pretty much as expected.

but……

During the second phase of clinical trials, I had almost spent all my savings and even mortgaged my house. Now I only have a few hundred thousand yuan left.

Even if you take out a bank loan or max out your credit card, you can probably only get less than 200 million. Where can you find the remaining millions?
He frowned inadvertently, and Ren Xiaomin on the side obviously saw Zhang Yang's trouble.

After thinking for a moment, he said:

"Zhang Yang, if you really want to continue to advance the Phase III clinical trial, I do have some savings, probably around 200 million."

"If the difference is still far, I can mortgage my house as well, and I should be able to borrow another 400 million, which will add up to about 600 million."

"If you need it, you can use this money first. When the new drug is on the market and you make money, you can pay me back."

Zhang Yang looked at Ren Xiaomin with some emotion.

To be honest, in the past few months of working with Ren Xiaomin, apart from being a little soft-hearted, his character and personality are really impeccable.

He was no longer polite and gently patted Ren Xiaomin on the shoulder:

"Brother Ren, I won't be polite with you."

"But can you make the decision on mortgaging the house? Why don't you discuss it with my sister-in-law?"

Ren Xiaomin suddenly shuddered, then hurriedly patted his chest:
"Don't worry, the master has the final say on family matters!"

"Haha."

Zhang Yang laughed.

……

Of course, Zhang Yang was not really worried that this incident would cause family conflicts in Ren Xiaomin. Both he and Ren Xiaomin were very clear about the value of "Qingshan Avaqubopa".

Once the phase III trial is completed and the product is on the market, the mere 600 million will be nothing to mention.

After making up their minds, both of them felt a lot more relaxed. In the next few days, Zhang Yang became less anxious and began to slow down his efforts to contact pharmaceutical companies.

Similarly, other pharmaceutical companies are no longer in a hurry. In the past few days, everyone has learned about Zhang Yang's background through their own channels.

As rumored, Zhang Yang, the founder of Qingshan Pharmaceutical, even mortgaged his house and car. Obviously, funds are already very tight, and it is impossible to continue to advance the Phase III clinical trial without external support.

Without the money to push forward the Phase III clinical trial, it means that the "Qingshan Avatrombopag" in his hands must be traded!

The pharmaceutical companies were completely relieved. In addition to continuing to communicate with Zhang Yang normally, almost everyone was waiting for Zhang Yang to speak first.

Once Zhang Yang takes the initiative, the offensive and defensive situations will change!
In this wonderful environment, the two sides formed a delicate balance. About three weeks later, Zhang Yang raised about 100 million yuan. Together with the 600 million yuan borrowed by Ren Xiaomin, the funds in his hands reached 800 million yuan.

The funds are in place, the second phase has ended, and now we are waiting for the approval of the third phase clinical trial plan of "Qingshan Avatrombopag".

Two weeks later, the Phase III clinical trial plan of "Qingshan Avatrombopag" was approved!
Zhang Yang did not expect that the "Phase III Clinical Trial Plan" submitted to the review center would be approved so quickly. After he carefully read the approval document, he was shocked!
In the Phase III clinical trial protocol they submitted, the number of subjects was 600, but now!
The number of subjects was increased to 1800 by the review center!
That is,

If you want to complete the Phase III clinical trial and obtain marketing approval, you must provide clinical data of 1800 people!

And most importantly!

He suddenly realized that all his plans were disrupted!
(End of this chapter)